206 related articles for article (PubMed ID: 31134194)
1. Beyond the Present Constraints That Prevent a Wide Spread of Tissue Engineering and Regenerative Medicine Approaches.
O'Donnell BT; Ives CJ; Mohiuddin OA; Bunnell BA
Front Bioeng Biotechnol; 2019; 7():95. PubMed ID: 31134194
[TBL] [Abstract][Full Text] [Related]
2. Ethical considerations in tissue engineering research: Case studies in translation.
Baker HB; McQuilling JP; King NM
Methods; 2016 Apr; 99():135-44. PubMed ID: 26282436
[TBL] [Abstract][Full Text] [Related]
3. Tissue engineered constructs: perspectives on clinical translation.
Lu L; Arbit HM; Herrick JL; Segovis SG; Maran A; Yaszemski MJ
Ann Biomed Eng; 2015 Mar; 43(3):796-804. PubMed ID: 25711151
[TBL] [Abstract][Full Text] [Related]
4. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives.
Bakopoulou A
J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189
[TBL] [Abstract][Full Text] [Related]
5. Turning Regenerative Medicine Breakthrough Ideas and Innovations into Commercial Products.
Bayon Y; Vertès AA; Ronfard V; Culme-Seymour E; Mason C; Stroemer P; Najimi M; Sokal E; Wilson C; Barone J; Aras R; Chiesi A
Tissue Eng Part B Rev; 2015 Dec; 21(6):560-71. PubMed ID: 26179129
[TBL] [Abstract][Full Text] [Related]
6. From bench to FDA to bedside: US regulatory trends for new stem cell therapies.
Knoepfler PS
Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841
[TBL] [Abstract][Full Text] [Related]
7. Recent Progress in European Advanced Therapy Medicinal Products and Beyond.
Yu TTL; Gupta P; Ronfard V; Vertès AA; Bayon Y
Front Bioeng Biotechnol; 2018; 6():130. PubMed ID: 30298129
[TBL] [Abstract][Full Text] [Related]
8. New ways of insulin delivery.
Heinemann L
Int J Clin Pract Suppl; 2011 Feb; (170):31-46. PubMed ID: 21323811
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a preclinical ovine model for tibial segmental bone defect repair by applying bone tissue engineering strategies.
Reichert JC; Epari DR; Wullschleger ME; Saifzadeh S; Steck R; Lienau J; Sommerville S; Dickinson IC; Schütz MA; Duda GN; Hutmacher DW
Tissue Eng Part B Rev; 2010 Feb; 16(1):93-104. PubMed ID: 19795978
[TBL] [Abstract][Full Text] [Related]
10. Translating Dental, Oral, and Craniofacial Regenerative Medicine Innovations to the Clinic through Interdisciplinary Commercial Translation Architecture.
Taylor DP; Yoshida M; Fuller K; Giannobile WV; Sfeir CS; Wagner WR; Kohn DH
J Dent Res; 2021 Sep; 100(10):1039-1046. PubMed ID: 33906502
[TBL] [Abstract][Full Text] [Related]
11. An assessment of the factors affecting the commercialization of cell-based therapeutics: a systematic review protocol.
Pettitt D; Arshad Z; Davies B; Smith J; French A; Cole D; Bure K; Dopson S; DiGiusto D; Karp J; Reeve B; Barker R; Holländer G; Brindley D
Syst Rev; 2017 Jun; 6(1):120. PubMed ID: 28651620
[TBL] [Abstract][Full Text] [Related]
12. Market access pathways for cell therapies in France.
Rémuzat C; Toumi M; Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123176
[TBL] [Abstract][Full Text] [Related]
13. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
14. Scaffold engineering: a bridge to where?
Hollister SJ
Biofabrication; 2009 Mar; 1(1):012001. PubMed ID: 20811095
[TBL] [Abstract][Full Text] [Related]
15. Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals.
Elsallab M; Bravery CA; Kurtz A; Abou-El-Enein M
Mol Ther Methods Clin Dev; 2020 Sep; 18():269-279. PubMed ID: 32637456
[TBL] [Abstract][Full Text] [Related]
16. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
[TBL] [Abstract][Full Text] [Related]
17. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
18. Are there specific translational challenges in regenerative medicine? Lessons from other fields.
Gardner J; Faulkner A; Mahalatchimy A; Webster A
Regen Med; 2015; 10(7):885-95. PubMed ID: 26541074
[TBL] [Abstract][Full Text] [Related]
19. Prospects for translational regenerative medicine.
Chen FM; Zhao YM; Jin Y; Shi S
Biotechnol Adv; 2012; 30(3):658-72. PubMed ID: 22138411
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory and Neuropathic Pain From Bench to Bedside: What Went Wrong?
Yezierski RP; Hansson P
J Pain; 2018 Jun; 19(6):571-588. PubMed ID: 29307749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
